Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H R Silberman

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Transactions of the Association of American Physicians|January 1, 1976
The effect of synthetic androgens in hereditary angioneurotic edema: alteration of C1 inhibitor and C4 levelsW F Rosse, G L Logue, H R Silberman, et al.
Revista Venezolana De Urologia|July 1, 1970
[Hyperuricosuria controlled with allopurinol: a new concept in the prevention of uric acid calculi]E E Anderson, R W Rudles, H R Silberman, et al.
Journal of the American Geriatrics Society|May 1, 1983
Effects of age on responses to treatment and survival of patients with multiple myelomaH J Cohen, H R Silberman, W Forman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1986
Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatmentH J Cohen, A A Bartolucci, W B Forman, et al.
Cancer Clinical Trials|January 1, 1981
Assessment of myeloma maintenance regimen of prednisone. Adriamycin, imuran, and vincristine in a murine plasmacytoma modelV K Ghanta, H J Cohen, H R Silberman, et al.
Experimental Hematology|January 1, 1979
Autologous marrow transplantation for patients with acute myelogenous leukemia--a preliminary reportJ W Fay, H R Silberman, J O Moore, et al.
Blood|October 1, 1979
Combination chemotherapy with intermittent 1-3-bis(2-chloroethyl)1-nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myelomaH J Cohen, H R Silberman, W E Larsen, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Transactions of the Association of American Physicians|January 1, 1976
The effect of synthetic androgens in hereditary angioneurotic edema: alteration of C1 inhibitor and C4 levelsW F Rosse, G L Logue, H R Silberman, et al.
Revista Venezolana De Urologia|July 1, 1970
[Hyperuricosuria controlled with allopurinol: a new concept in the prevention of uric acid calculi]E E Anderson, R W Rudles, H R Silberman, et al.
Journal of the American Geriatrics Society|May 1, 1983
Effects of age on responses to treatment and survival of patients with multiple myelomaH J Cohen, H R Silberman, W Forman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1986
Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatmentH J Cohen, A A Bartolucci, W B Forman, et al.
Cancer Clinical Trials|January 1, 1981
Assessment of myeloma maintenance regimen of prednisone. Adriamycin, imuran, and vincristine in a murine plasmacytoma modelV K Ghanta, H J Cohen, H R Silberman, et al.
Experimental Hematology|January 1, 1979
Autologous marrow transplantation for patients with acute myelogenous leukemia--a preliminary reportJ W Fay, H R Silberman, J O Moore, et al.
Blood|October 1, 1979
Combination chemotherapy with intermittent 1-3-bis(2-chloroethyl)1-nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myelomaH J Cohen, H R Silberman, W E Larsen, et al.
Pageof 2